

## DAFTAR PUSTAKA

1. Rossi ED, Pantanowitz L, Hornick JL. A worldwide journey of thyroid cancer incidence centred on tumour histology. *Lancet Diabetes Endocrinol.* 2021 Apr 1;9(4):193-4.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
3. International Agency of Research on Cancer. GLOBOCAN 2020. Estimated cancer incidence, mortality, and prevalence worldwide in 2020. [cited 2022 August 14]. Available from: <https://gco.iarc.fr/today/data/factsheets/cancers/32-Thyroid-fact-sheet.pdf>
4. World Health Organization. Cancer Country Profile: Indonesia Burden of Cancer. 2020. [cited 2022 August 14]. Available from: <https://www.who.int/publications/m/item/cancer-idn-2020>
5. International Agency of Research on Cancer. GLOBOCAN 2020. Estimated cancer incidence, mortality, and prevalence in Indonesia in 2020. [cited 2022 August 16]. Available from: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>
6. Dinas Kesehatan Provinsi Sumatera Barat: Profil Kesehatan Provinsi Sumatera Barat. 2019.
7. Farhan MA. Gambaran hasil biopsi aspirasi jarum halus (BAJAH) massa di leher pada pasien RSUP DR. M. Djamil Padang tahun 2019-2020. Skripsi. Universitas Andalas Padang; 2021.
8. Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated thyroid cancer-treatment: State of the art. *Int. J. Mol. Sci.* 2017;18:1-17.
9. Sutherland R, Tsang V, Clifton-Bligh RJ, Gild ML. Papillary thyroid microcarcinoma: is active surveillance always enough ?. *Clin Endocrinol.* 2021:811-17.
10. Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2019. Available from: <https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdz400/5573120>
11. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. *Thyroid.* 2016;26(1):1-133. doi: 10.1089/thy.2015.0020

12. Adham M, Aldino N. Diagnosis dan tatalaksana karsinoma tiroid berdiferensiasi. *Oto Rhino Laryngologica Indonesiana*. 2018;48(2):197-209.
13. Silaghi H, Lozovanu V, Georgescu CE, Pop C, Nasui BA, Catoi AF, et al. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer. *Int J Mol Sci*. 2022;23:1-27.
14. Campenni A, Barbaro D, Guzzo M, Capocchetti F, Giovannella L. Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts. *Endocrine*. 2020;70:280–91.
15. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. *Eur J Surg Oncol*. 2017;44:307–15.
16. Gartner R, Rank P, Ander B. The role of iodine and 6-iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. *Hormones*. 2010;9(1):60-66.
17. De La Vieja A, Santisteban P. Role of iodide metabolism in physiology and cancer. *Endocr Relat Cancer*. 2018;25(4):R225-45.
18. Milanesi A, Brent GA. Iodine and Thyroid Hormone Synthesis, Metabolism, and Action. In: *Molecular, Genetic, and Nutritional Aspects of Major and Trace Minerals*. Elsevier Inc. 2017:p. 143–50.
19. Soriano O, Delgado G, Anguino B, Petrosyan P, Molina-Servin ED, Gonsebatt ME, et al. Antineoplastic effect of iodine and iodide in dimethylbenz[a]anthracene-induced mammary tumors: association between lactoperoxidase and estrogen-adduct production. *End Related Cancer*. 2011;18:529-39.
20. Nava-Villalba M, Nunez-Anita RE, Bontempo A, Aceves C. Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone. *Molecular Cancer*. 2015;14(168):1-11.
21. Guyton AC, Hall JE. *Buku ajar fisiologi kedokteran*. Edisi 12. Singapore: Elsevier; 2016.
22. Panneels V, Juvenal G, Boeynaems JM, Dumont JE, van Sande J. Iodide Effects on the Thyroid: Biochemical, Physiological, Pharmacological, and Clinical Effects of Iodide in the Thyroid. In: *Comprehensive Handbook of Iodine: Nutritional, Biochemical, Pathological and Therapeutic Aspects*. Elsevier.2009:p.303–14.
23. Aceves C, Mendieta I, Anguiano B, Delgado-González E. Molecular iodine has extrathyroidal effects as an antioxidant, differentiator, and immunomodulator. *Inj. J. Mol. Sci*. 2021;22:1–15.

24. Pirahanchi Y, Toro F, Jialal I. Physiology, Thyroid stimulating hormone [Internet]. 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK499850/>
25. Xie X, Shi X, Guan H, Guo Q, Fan C, Dong W, et al. P21-activated kinase 4 involves TSH induced papillary thyroid cancer cell proliferation. *Oncotarget*. 2017;8(15):24882-891.
26. Djoko Rianto BU, Wibowo AS, Herdini C. The difference in thyroid stimulating hormone levels between differentiated carcinoma and benign enlargement. *Int Arch Otorhinolaryngol*. 2020;24(1):E73–9.
27. Xiang J, Wang X, Wang Z, Wu Y, Li D, Shen Q, et al. Effect of different iodine concentrations on well-differentiated thyroid cancer cell behavior and its inner mechanism. *Cell Biochem Biophys*. 2015;71(1):299–305.
28. Rosner H, Moller W, Groebner S, Torremante P. Antiproliferative/Cytotoxic Effect of Molecular Iodine, Povidone-Iodine and Lugol's Solution in Different Human Carcinoma Cell Lines. *Oncol Lett*. 2016;12:2159-62.
29. Simbolon D, Hapsari T. Iodine consumption and linear growth of children under five years old in malabero coastal area, bengkulu city. *Jurnal Kesehatan Masyarakat*. 2018 Sep 23;14(1):140–6.
30. Hatch-McChesney A, Lieberman HR. Iodine and Iodine Deficiency: A Comprehensive Review of a Re-Emerging Issue. *MDPI*. 2022;14:2-11.
31. Niwattisaiwong S, Burman KD, Li-ng M. Iodine deficiency: clinical implications. *Cleve Clin J Med*. 2017;84(3):236-44.
32. Sorrenti S, Baldini E, Pironi D, Lauro A, D'Orazi V, Tartaglia F, et al. Iodine: Its role in thyroid hormone biosynthesis and beyond. *Nutrients*. MDPI. 2021; 13:1-11.
33. Pereira SS, Lobato CB, Monteiro MP. Cell signaling within endocrine glands: thyroid, parathyroids and adrenal glands. *Tissue-Specific Cell Signaling*. 2020: 63-92.
34. Dumont JE, Maenhaut C, Christophe D, Roger PP. Thyroid Regulatory Factors. In: *Endocrinology: Adult and Pediatric*. Elsevier Inc. 2016:p. 1297-1321.
35. Zhang D, Xu X, Li J, Yang X, Sun J, Wu Y, et al. High iodine effects on the proliferation, apoptosis, and migration of papillary thyroid carcinoma cells as a result of autophagy induced by BRAF kinase. *Biomedicine and Pharmacotherapy*. 2019 Dec 1;120.

36. Thyroid cancer basics. ThyCa: Thyroid Cancer Survivors' Association, inc [Internet]. 2018. Tersedia pada: [www.thyca.org](http://www.thyca.org)
37. Manzil FFP, Kaur H. Radioactive iodine for thyroid malignancies. StatPearls-NCBI Bookshelf [Internet]. 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK580567/>
38. Zhang D, Tang J, Kong D, Cui Q, Wang K, Gong Y, et al. Impact of gender and age on the prognosis of differentiated thyroid carcinoma: a retrospective analysis based on SEER. *Horm Cancer*. 2018;9(5):361–70.
39. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. *Lancet*. 2016;388:2783–95.
40. Feig BW, Ching CD. The MD anderson surgical oncology handbook. Edisi 6. China: Wolters Kluwer; 2019. p.746-93.
41. Park KS, Kim SH, Oh JH, Kim SY. Highly accurate diagnosis of papillary thyroid carcinomas based on personalized pathways coupled with machine learning. *Brief Bioinform*. 2021;22(4):2-12.
42. Pfeifer A, Wojtas B, Oczko-Wojciechowska M, Kukulska A, Czarniecka A, Eszlinger M, et al. Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues. *BMC Med Genomics*. 2013;6:2-10.
43. Master SR, Burns B. Medullary thyroid cancer. [Updated 2023 Feb 15]. In : StatPearls-NCBI Bookshelf [Internet]. 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459354/>
44. Du X, Cao D, Yan F, Gao Y, Chang H, Wei B. Clinicopathological characteristics of mucinous variant of anaplastic thyroid carcinoma. *Acta Endocrinol (Buc)*. 2020; 16(3):377–8.
45. Limaiem F, Kashyap, Naing PTN, Giwa Al O. Anaplastic thyroid cancer. [Updated 2023 Jan 1]. In : StatPearls-NCBI Bookshelf [Internet]. 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538179/>
46. Arrangoiz R, Cordera F, Caba D, Moreno E, Luque-de-Leon E, Munoz M. Thyroid cancer [Internet]. *Int J Otorhinolaryngol Head Neck surg*. 2019;08(06):217–70. doi: <https://doi.org/10.4236/ijohns.2019.86024>
47. American Cancer Society. Test for thyroid Cancer. *Cancer.org*.2019. Available from: <https://www.cancer.org/cancer/types/thyroid-cancer/detect/on-diagnosis-staging/how-diagnosed.html>



48. Jarzab B, Dedecjus M, Handkiewicz-Junak D, Lange D, Lewiński A, Nasierowska-Guttmejer A, et al. Diagnostics and treatment of thyroid carcinoma. *Endokrynol Pol.* 2016;67(1):74–145.
49. Aslantürk ÖS. In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages. 2018:1-18.
50. Nurani PS. Uji sitotoksik kombinasi ekstrak etanol 96% benalu alpukat (*Dendrothoe petandra* (L) Miq) dengan cisplatin pada sel kanker serviks hela. Skripsi. Fakultas Kedokteran dan Ilmu Kesehatan Universitas Islam Negeri Maulana Malik Ibrahim Malang. 2018. Available from: <http://etheses.uin-malang.ac.id/13429/1/14670005.pdf>
51. Watuguly TW, Samsuria IK. Aspek Dasar Molekuler Proliferasi dan Apoptosis. Bandung: Alfabeta; 2018.
52. Filbert, Koleangan HSJ, Runtuwene MRJ, Kamu VS. Penentuan Aktivitas antioksidan Berdasarkan Nilai IC<sub>50</sub> Ekstrak Metanol dan Frakti Hasil Partisinya pada Kulit Biji Pinang Yaki (*Areca vestiaria Giseke*). *Jurnal MIPA UNSRAT.* 2014;3(2):149-54.
53. Safitri RA, Saptarini O, Sunarni T. Uji aktivitas sitotoksik, ekspresi p53, dan Bcl-2 dari ekstrak fraksi herba kelakai (*stenochleana palustris* (Burm.F.) bed.) terhadap sel kanker payudara T47D. *Jurnal Biotek Medisiana Indonesia.* 2020;9(2):113-27.
54. Cancer Chemoprevention Research Center. Protokol Uji Sitotoksik Metode MTT.[CCRC-03-010-02]. CCRC Fakultas Farmasi UGM. 2013.
55. Dona R, Sulistyani N, Nurani LH. Uji sitotoksitas dan antiproliferative ekstrak etanol daun leunca (*Solanum nigrum, L*) terhadap sel raji. *Pharmaciana.* 2016;6(2):181-90.
56. Liu XH, Chen GC, Vlantis AC, Tse GM, Hasselt CA. Iodine induced apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells. *Mol Cell Endocrinol.* 2010:128-35.
57. Rosner H, Torremante P, Moller W, Gartner R. Antiproliferative/Citotoxic Activity of Molecular Iodine and Iodolactones in Various Human Carcinoma Cell Lines. No Interfering with EGF-signaling, but Evidence for Apoptosis. *Exp Clin Endocrinol Diabetes.* 2010;118:410-19.
58. Yang Y, Cao Y. The impact of VEGF on cancer metastasis and systemic disease. Vol. 86, *Seminars in Cancer Biology.* Academic Press. 2022:251–61.
59. Mendieta I, Nunez-Anita RE, Nava-Villalba M, Zambrano-Estrada X, Delgado-Gonzalez E, Anguiano B, et al. Molecular iodine exerts

antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts. *BMC Cancer*. 2019 Mar 22;19(1):2-12.

60. Aranda N, Sosa S, Delgado G, Aceves C, Anguiano B. Uptake and antitumoral effects of iodine and 6-iodolactone in differentiated and undifferentiated human prostate cancer cell lines. *The Prostate*. 2012;73(1):1-11.
61. Torremante PE, Rosner H. Antiproliferative Effects of Molecular Iodine in Cancers. Vol. 5, *Current Chemical Biology*. 2011;5:168-76.

